ORAL02.01: Safety and Efficacy of Single-Agent Rovalpituzumab Tesirine, a DLL3-Targeted ADC, in Recurrent or Refractory SCLC: Topic: Medical Oncology
Bauer, T.M.; Spigel, D.; Ready, N.; Morgensztern, D.; Glisson, B.S.; Byers, L.A.; Burris, H.; Robert, F.; Strickland, D.K.; Pietanza, M.C.; Govindan, R.; Dylla, S.J.; Peng, S.; Rudin, C.
Journal of Thoracic Oncology 11(11s): S252-S253
2016
ISSN/ISBN: 1556-1380 PMID: 27969444 DOI: 10.1016/j.jtho.2016.09.010
Accession: 060050452
Full Text Article emailed within 0-6 h: $19.90
Related References
Spigel, D; Pietanza, M Catherine; Bauer, T; Ready, N; Morgensztern, D; Glisson, B S.; Byers, L Averett; Johnson, M; Burris, H; Robert, F; Han, T; Bheddah, S; Theiss, N; Watson, S; Mathur, D; Vennapusa, B; Strickland, D; Zayed, H; Dylla, S; Peng, S; Govindan, R; Rudin, C 2017: OA05.03 Single-Agent Rovalpituzumab Tesirine, a Delta-Like Protein 3 (DLL3)-Targeted Antibody-Drug Conjugate (ADC), in Small-Cell Lung Cancer (SCLC) Journal of Thoracic Oncology 12(1): S260-S261Tanaka, K.; Udagawa, H.; Akamatsu, H.; Takeda, M.; Kanda, S.; Yasuda, I.; Okubo, S.; Wong, S.; Scripture, C.; Tamura, T.; Okamoto, I. 2018: Phase 1 study on safety and PK of rovalpituzumab tesirine (Rova-T) in Japanese patients with advanced, recurrent SCLC Annals of Oncology: Official Journal of the European Society for Medical Oncology 29 Suppl. 7: Vii57
Blackhall, F.; Jao, K.; Greillier, L.; Cho, B.C.; Penkov, K.; Reguart, N.; Majem, M.; Nackaerts, K.; Syrigos, K.; Hansen, K.; Schuette, W.; Cetnar, J.; Cappuzzo, F.; Okamoto, I.; Erman, M.; Langer, S.W.; Kato, T.; Groen, H.; Sun, Z.; Luo, Y.; Tanwani, P.; Caffrey, L.; Komarnitsky, P.; Reinmuth, N. 2021: Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High SCLC: Results from the Phase 3 TAHOE Study Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 16(9): 1547-1558
Morgensztern, D.; Besse, B.; Greillier, L.; Santana-Davila, R.; Ready, N.; Hann, C.L.; Glisson, B.S.; Farago, A.F.; Dowlati, A.; Rudin, C.M.; Le Moulec, S.; Lally, S.; Yalamanchili, S.; Wolf, J.ür.; Govindan, R.; Carbone, D.P. 2019: Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results from the Phase Ii TRINITY Study Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 25(23): 6958-6966
Uprety, D.; Remon, J.; Adjei, A.A. 2021: All that Glitters Is not Gold: the Story of Rovalpituzumab Tesirine in SCLC Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 16(9): 1429-1433
Calvo, E.; Spira, A.; Miguel, M.ía.d.; Kondo, S.; Gazzah, A.; Millward, M.; Prenen, H.; Rottey, S.; Warburton, L.; Alanko, T.; Cassier, P.A.; Yoh, K.; Italiano, A.; Moreno, V.; Peltola, K.; Seto, T.; Toyozawa, R.; Afar, D.E.; Englert, S.; Komarnitsky, P.; Lambert, S.; Parikh, A.; Vosganian, G.; Gao, B. 2021: Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer Cancer Treatment and Research Communications 28: 100405
Udagawa, H.; Akamatsu, H.; Tanaka, K.; Takeda, M.; Kanda, S.; Kirita, K.; Teraoka, S.; Nakagawa, K.; Fujiwara, Y.; Yasuda, I.; Okubo, S.; Shintani, M.; Kosloski, M.P.; Scripture, C.; Tamura, T.; Okamoto, I. 2019: Phase i safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer Lung Cancer 135: 145-150
Udagawa, H.; Akamatsu, H.; Tanaka, K.; Takeda, M.; Kanda, S.; Kirita, K.; Teraoka, S.; Nakagawa, K.; Fujiwara, Y.; Yasuda, I.; Okubo, S.; Shintani, M.; Kosloski, M.P.; Scripture, C.; Tamura, T. 2019: Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer Lung Cancer 135: 145-150
Hann, C.L.; Burns, T.F.; Dowlati, A.; Morgensztern, D.; Ward, P.J.; Koch, M.M.; Chen, C.; Ludwig, C.; Patel, M.; Nimeiri, H.; Komarnitsky, P.; Camidge, D.R. 2021: A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients with Extensive-Stage SCLC Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 16(9): 1582-1588
Rudin, C.M.; Pietanza, M.C.; Bauer, T.M.; Ready, N.; Morgensztern, D.; Glisson, B.S.; Byers, L.A.; Johnson, M.L.; Burris, H.A.; Robert, F.; Han, T.H.; Bheddah, S.; Theiss, N.; Watson, S.; Mathur, D.; Vennapusa, B.; Zayed, H.; Lally, S.; Strickland, D.K.; Govindan, R.; Dylla, S.J.; Peng, S.L.; Spigel, D.R. 2017: Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study LANCET. Oncology 18(1): 42-51
Hochmair, M.J.; Weinlinger, C.; Fabikan, H.; Koger, R.; Krenbeck, D.; Huemer, F.; Illini, O.M.; Kulaksiz, M.; Valipour, A.; Burghuber, O.C. 2019: Real-life experience with the implementation of DLL3 staining and the subsequent treatment with rovalpituzumab tesirine in heavily pretreated SCLC patients Annals of Oncology: Official Journal of the European Society for Medical Oncology 30 Suppl. 2: Ii23
Malhotra, J.; Nikolinakos, P.; Leal, T.; Lehman, J.; Morgensztern, D.; Patel, J.D.; Wrangle, J.M.; Curigliano, G.; Greillier, L.; Johnson, M.L.; Ready, N.; Robinet, G.; Lally, S.; Maag, D.; Valenzuela, R.; Blot, V.; Besse, B. 2021: A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination with Nivolumab Plus or Minus Ipilimumab in Patients with Previously Treated Extensive-Stage SCLC Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 16(9): 1559-1569
Johnson, M.L.; Zvirbule, Z.; Laktionov, K.; Helland, A.; Cho, B.C.; Gutierrez, V.; Colinet, B.ît.; Lena, H.; Wolf, M.; Gottfried, M.; Okamoto, I.; van der Leest, C.; Rich, P.; Hung, J.-Y.; Appenzeller, C.; Sun, Z.; Maag, D.; Luo, Y.; Nickner, C.; Vajikova, A.; Komarnitsky, P.; Bar, J. 2021: Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients with Extensive-Stage-SCLC: Results from the Phase 3 MERU Study Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 16(9): 1570-1581
Hann, C.; Burns, T.; Dowlati, A.; Morgensztern, D.; Koch, M.; Chang, Y.; Komarnitsky, P.; Ludwig, C.; Nimeiri, H.; Camidge, D. 2019: A phase i study evaluating rovalpituzumab tesirine (ROVA-T) in frontline treatment of patients (pts) with extensive stage small cell lung cancer (ES-SCLC) Annals of Oncology 30: V711-V712
Calvo, E.; Spira, A.; Prenen, H.; Ohe, Y.; Rottey, S.; Gazzah, A.; Millward, M.; Moreno, V.; Italiano, A.; Alanko, T.; Yoh, K.; Cassier, P.; Seto, T.; Afar, D.; Englert, S.; Komarnitsky, P.; Lambert, S.; Parikh, A.; Vosganian, G.; Gao, B. 2019: Phase i open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABBV-181 and rovalpituzumab tesirine (ROVA-T) in patients with small cell lung cancer Annals of Oncology 30: V715-V716
Hou, J.L.; Bridges, A.G. 2018: Phototoxic drug reaction with the novel agent rovalpituzumab tesirine International Journal of Dermatology 57(3): E17-E19
Van Den Borg, R.; Leonetti, A.; Tiseo, M.; Giovannetti, E.; Peters, G.J. 2019: Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine Expert Review of Anticancer Therapy 19(6): 461-471
Gupta, N.; Labotka, R.; Liu, G.; Hui, A-Min.; Venkatakrishnan, K. 2016: Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study Investigational new Drugs 34(3): 338-346
Antonia, S.J.; Gettinger, S.N.; Goldman, J.; Brahmer, J.; Borghaei, H.; Chow, L.Q.; Ready, N.E.; Gerber, D.E.; Juergens, R.; Shepherd, F.; Laurie, S.A.; Young, T.; Geese, W.J.; Agrawal, S.; Li, X.; Hellmann, M.D. 2016: ORAL01.03: Check Mate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC: Topic: Medical Oncology Journal of Thoracic Oncology 11(11s): S250-S251
Schuster, M.W.; Canales, M. A.; Westin, J.; Zijlstra, J. M.; Follows, G. A.; Karmali, R.; Kalakonda, N.; Goy, A.H.; Casasnovas, R.; Vermaat, J.; Van Den Neste, E.; Choquet, S.; Thieblemont, C.; Cavallo, F.; De La Cruz, M.d.F.; Hill, B.T.; Tilly, H.; Kassam, S.; Bouabdallah, R.; Jaeger, U.; Gurion, R.; Caimi, P.; Martin, P.; Davies, A.; Smith, S.M.; Collins, G.P.; Offner, F.C.; Salles, G.; Ma, X.; Corona, K.; Saint-Martin, J.; Joshi, A.A.; Chamoun, K.; Wang, H.; Shah, J.J.; Shacham, S.; Kauffman, M. G.; Maerevoet, M. 2020: Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): a Post-Hoc Analysis of the Sadal Pivotal Study Blood 136(Supplement 1: 5-6